![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Fowler VG, O’Brien SM, Muhlbaier LH, et al. Clinical predictors of major infections after cardiac surgery. Circulation 2005;112[Suppl I]:358i–65i
- Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology Web Site. Available at: http://www.acc.org/clinical/guidelines/cabg/cabg.pdf
- Catron DM, Lange Y, Borensztajn J, et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immunity 2004;72:1036–42
- Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000;10:1760–3
- Liappis AP, Kan VL, Rochester CG, et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352–7
- Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080–6
- Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Resp Res 2005;6:82 Online. doi:10.1186/1465–9921–6–82
- Van de Garde EMW, Souverein PC, Hoss AW, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;11:957–61
- Ali IS, Buth KJ. Impact of preoperative statin use on sepsis and deep sternal wound infection following cardiac surgery. Circulation 2005;111:e320
- Society of Thoracic Surgeons (STS) national database. STS adult cardiac database – definitions of terms. Available at: www.sts.org/doc/8428 (accessed 11/8/2006)
- Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880–5
- Hackman DG, Mamandi M, Redelmeir DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413–18
- Catron DM, Lange Y, Borensztajn J, et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immunity 2004;72:1036–42
- Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 2004;15:637–43
- White CM. HMg CoA Reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary 2002;37:588–93
- Masters BA, Palmoski MJ, Flint O, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995;131: 163–74
- Del Real G, Jiminez-Baranda S, Mira S, et al. Statins inhibit HIV-1 infection by downregulating Rho activity. J Exp Med 2004;200:541–7
- Giguere JF. Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004;78:12062–5
- Potena L, Frascaroli G, Grigioni F, et al. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004;109:532–6